JW to conduct Phase I trial for new anticancer medicine
Published: 2011-05-13 06:57:00
Updated: 2011-05-13 06:57:00
JW Pharmaceutical has recently announced that it will conduct Phase I clinical trial for CWP231A, a candidate anticancer medicine that interrupts biochemical signals to eradicate leukemia stem cells without affecting normal cells, in the United States within this month.
Last month, the company...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
